Pelthos Therapeutics Inc. (PTHS) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Pelthos Therapeutics reported revenue of $16.8M. Net income was -$43.3M (a -257.9% net margin), or -$23.04 per diluted share. Gross margin was 76.3% and operating margin was -193.1%. Operating activities generated -$22.6M of cash, leaving -$22.7M of free cash flow. At fiscal year end, Pelthos Therapeutics held $130.4M in total assets against $91.5M in total liabilities, including $18.0M of cash and equivalents.
Open the full interactive Pelthos Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Pelthos Therapeutics Key Stats
| Share Price | $20.29 |
|---|---|
| Market Cap | $71.8M |
| 52-Week Range | $18.19 – $37.42 |
| Shares Outstanding | 3.5 million (basic, 2026 Q2) |
Pelthos Therapeutics Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $0 | $0 | $16.8M |
| Cost of Goods Sold | — | — | $4.0M |
| Gross Profit | — | — | $12.8M |
| Operating Income | -$6.9M | -$7.6M | -$32.4M |
| Pre-Tax Income | -$7.4M | -$8.0M | -$50.7M |
| Income Tax | — | — | -$7.4M |
| Net Income | -$7.4M | -$8.0M | -$43.3M |
| Diluted EPS | — | -$14.30 | -$23.04 |
Pelthos Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $7.4M | $9.4M | $10.9M | $15.6M |
| Net Income | -$16.2M | -$21.7M | -$10.2M | -$23.4M |
| Diluted EPS | -$5.30 | -$11.52 | -$3.09 | -$6.62 |
Pelthos Therapeutics Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $100,000 | — | $18.0M |
| Current Assets | $96,391 | $1.4M | $53.4M |
| Total Assets | $96,391 | $1.4M | $130.4M |
| Current Liabilities | $6.5M | $4.1M | $26.0M |
| Total Long-Term Debt | $750,082 | $131,868 | $31.4M |
| Total Liabilities | $6.5M | $4.1M | $91.5M |
| Shareholders' Equity | -$6.4M | -$2.7M | $38.9M |
Pelthos Therapeutics Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$981,031 | -$5.8M | -$22.6M |
| Cash From Investing | — | — | -$5.2M |
| Cash From Financing | $1.0M | $6.2M | $45.3M |
| Free Cash Flow | — | — | -$22.7M |
Figures from Pelthos Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Pelthos Therapeutics financials page for every line item.
Pelthos Therapeutics Company Profile
| Ticker | PTHS |
|---|---|
| Exchange | NYSE |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Durham, North Carolina |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001919246 |
Frequently Asked Questions
What was Pelthos Therapeutics' revenue in fiscal 2025?
Pelthos Therapeutics (PTHS) reported revenue of $16.8M for fiscal 2025.
What is Pelthos Therapeutics' annual revenue history?
Pelthos Therapeutics' annual revenue by fiscal year: 2023: $0; 2024: $0; 2025: $16.8M.
What was Pelthos Therapeutics' net income in fiscal 2025?
Pelthos Therapeutics reported net income of -$43.3M for fiscal 2025.
What was Pelthos Therapeutics' earnings per share (EPS) in fiscal 2025?
Pelthos Therapeutics' diluted EPS was -$23.04 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Pelthos Therapeutics generate in fiscal 2025?
Pelthos Therapeutics generated -$22.7M of free cash flow in fiscal 2025.
What was Pelthos Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Pelthos Therapeutics reported revenue of $15.6M.
How much debt does Pelthos Therapeutics have?
Pelthos Therapeutics reported $31.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Pelthos Therapeutics are outstanding?
Pelthos Therapeutics reported a weighted average of 3.5 million basic shares outstanding in 2026 Q2.
What is Pelthos Therapeutics' market cap?
Based on its latest closing price, Pelthos Therapeutics (PTHS) has a market capitalization of about $71.8M.
When does Pelthos Therapeutics' fiscal year end?
Pelthos Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Pelthos Therapeutics headquartered?
Pelthos Therapeutics lists its business address in Durham, North Carolina in its SEC filings.
Pelthos Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →